Perspective Therapeutics, Inc. 8-K

What Happened
Perspective Therapeutics, Inc. (CATX) filed an 8-K on January 9, 2026 to announce that it issued a press release reporting updated interim data from its Phase 1/2a clinical trial of [212Pb]VMT-α-NET. The data relate to patients with unresectable or metastatic somatostatin receptor subtype 2-expressing neuroendocrine tumors (NETs) and are being presented at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) held January 8–10, 2026 in San Francisco. The press release is attached to the filing as Exhibit 99.1.

Key Details

• Filing date of Form 8-K: January 9, 2026.
• Event: Presentation of updated interim Phase 1/2a data for [212Pb]VMT-α-NET at ASCO GI (Jan 8–10, 2026).
• Indication: Unresectable or metastatic somatostatin receptor subtype 2-expressing neuroendocrine tumors (NETs).
• Press release disclosing the data is filed as Exhibit 99.1 and incorporated by reference; the 8-K was signed by CEO Johan (Thijs) Spoor.

Why It Matters
Updated interim clinical data are a key near-term informational event for a clinical-stage biotech like Perspective Therapeutics. Presentations at major conferences such as ASCO GI can affect investor interest, potential partnerships, and the perceived clinical progress of the company’s lead radiopharmaceutical candidate. This 8-K does not include financial results or detailed efficacy/safety figures in the filing itself—investors should review the attached press release (Exhibit 99.1) and any conference materials for the substantive data.